These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 803668)

  • 21. The release of prolactin by medroxy-progesterone acetate in human subjects.
    Chaudhury RR; Chompootaweep S; Dusitsin N; Friesen H; Tankeyoon M
    Br J Pharmacol; 1977 Mar; 59(3):433-4. PubMed ID: 557353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of medroxyprogesterone acetate on serum levels of LH, FSH, cortisol, and estrone in patients with endometrial carcinoma.
    Vesterinen E; Backas NE; Pesonen K; Stenman UH; Laatikainen T
    Arch Gynecol; 1981; 230(3):205-11. PubMed ID: 6787991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stimulated plasma prolactin levels in women using medroxyprogesterone acetate or an intrauterine device for contraception.
    Spellacy WN; Buhi WC; Birk SA
    Fertil Steril; 1975 Oct; 26(10):970-81. PubMed ID: 810369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of long term hormone replacement on plasma prolactin concentrations in women after oophorectomy.
    Barlow DH; Beastall GH; Abdalla HI; Elias-Jones J; Lindsay R; Hart DM
    Br Med J (Clin Res Ed); 1985 Feb; 290(6468):589-91. PubMed ID: 3918684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained prolactin release associated with precocious ovarian failure.
    Crosignani PG; Meschia M; Bruschi F; Parazzini F
    Gynecol Obstet Invest; 1995; 39(1):63-4. PubMed ID: 7890257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancer.
    Hedley DW; Christie M; Weatherby RP; Caterson ID
    Cancer Chemother Pharmacol; 1985; 14(2):112-5. PubMed ID: 3156002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medroxyprogesterone acetate (MPA) treatment of sexual acting out in men suffering from dementia.
    Cooper AJ
    J Clin Psychiatry; 1987 Sep; 48(9):368-70. PubMed ID: 2957362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long term effect of medroxyprogesterone acetate in human ovarian morphophysiology and sperm transport.
    Zañartu J; Pupkin M; Rosenberg D; Davansens A; Guerrero R; Rodriguez-Bravo R; Garcia-Huidobro M
    Fertil Steril; 1970 Jul; 21(7):525-33. PubMed ID: 4194300
    [No Abstract]   [Full Text] [Related]  

  • 29. Thombocyte function in relation to the long term application of medroxyprogesterone acetate as a female contraceptive agent.
    Mettler L; Shirwani D; Brunnberg FJ
    J Postgrad Med; 1979 Jul; 25(3):154-7. PubMed ID: 529167
    [No Abstract]   [Full Text] [Related]  

  • 30. Contraceptive use--efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days.
    Schwallie PC; Assenzo JR
    Fertil Steril; 1973 May; 24(5):331-9. PubMed ID: 4698589
    [No Abstract]   [Full Text] [Related]  

  • 31. Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma.
    Charig CR; Rundle JS
    Urology; 1989 Mar; 33(3):175-8. PubMed ID: 2465644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Return of ovulatory cyclicity following an intramuscular injection of medroxyprogesterone acetate (Provera).
    Kirton KT; Cornette JC
    Contraception; 1974 Jul; 10(1):39-45. PubMed ID: 4442263
    [No Abstract]   [Full Text] [Related]  

  • 33. Fibrinolytic activity of veins during use of depot medroxyprogesterone acetate as a contraceptive.
    Astedt B; Jeppsson S; Pandolfi M
    Fertil Steril; 1972 Jul; 23(7):489-92. PubMed ID: 5036595
    [No Abstract]   [Full Text] [Related]  

  • 34. The development of depot contraceptives.
    Shearman RP
    J Steroid Biochem; 1975 Jun; 6(6):899-902. PubMed ID: 1177432
    [No Abstract]   [Full Text] [Related]  

  • 35. Blood levels of medroxyprogesterone acetate after multiple injections of depoprovera or cycloprovera.
    Koetsawang S; Shrimanker K; Fotherby K
    Contraception; 1979 Jul; 20(1):1-4. PubMed ID: 477312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measurement of medroxyprogesterone acetate (Provera ) by radioimmunoassay.
    Cornette JC; Kirton KT; Duncan GW
    J Clin Endocrinol Metab; 1971 Sep; 33(3):459-66. PubMed ID: 4998975
    [No Abstract]   [Full Text] [Related]  

  • 37. Induced prolactin release in women under long-term medroxyprogesterone acetate treatment.
    Perez-Lopez FR; Roncero MC
    Obstet Gynecol; 1975 Mar; 45(3):263-6. PubMed ID: 803668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenohypophyseal function in bitches treated with medroxyprogesterone acetate.
    Beijerink NJ; Bhatti SF; Okkens AC; Dieleman SJ; Mol JA; Duchateau L; Van Ham LM; Kooistra HS
    Domest Anim Endocrinol; 2007 Feb; 32(2):63-78. PubMed ID: 16455223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pituitary reserve for gonadotrophins and prolactin in women under long-term use of depo-medroxyprogesterone acetate (DMPA) as a contraceptive.
    Mukasa FR; Sekadde-kigondu CB; Mati JK; Njoroge JK
    J Obstet Gynaecol East Cent Africa; 1982 Dec; 1(4):160-3. PubMed ID: 12313677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Behavior of basal and stimulated serum levels of prolactin, growth hormone and gonadotropins in females with chronic uremia].
    Rudolf K; Rudolf H; Rüting M; Falkenhagen D
    Z Gesamte Inn Med; 1988 Oct; 43(19):542-4. PubMed ID: 3145648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.